Please use this identifier to cite or link to this item:
Title: Efficacy of Rispens CV1988 Vaccine Against Challenge with Marek's Disease Viruses of Varying Virulence, Effects on Viral Kinetics and Field Application of a Rispens Specific qPCR Test
Contributor(s): Ralapanawe, Sithara (author); Walkden-Brown, Steve (supervisor)orcid ; Renz, Katrin (supervisor)
Conferred Date: 2016
Copyright Date: 2015
Open Access: Yes
Handle Link:
Abstract: Marek's disease (MD) is an economically important poultry disease, which is successfully controlled by imperfect vaccines. The imperfect vaccines for MD, herpesvirus of turkeys (HVT) and HVT/Gallid herpesvirus 3 (GaHV-3) (bivalent) are likely to have contributed to the observed increase in virulence which has led to sequential failure of these vaccines in some parts of the world. The Gallid herpesvirus 2 (GaHV-2, MDV-1) Rispens CVI988 vaccine, first developed in 1972, has not been affected by this failure and is considered to be the gold standard Marek's disease vaccine, being widely used worldwide to vaccinate long lived layers and breeders. Two experiments were designed to investigate this vaccine and its efficacy in Australia. An experiment in isolators investigated the protection provided by Rispens vaccine against Australian pathogenic GaHV-2 isolates of varying virulence (virulent, vMDV and very virulent vvMDV), and the kinetics of viral genome copy number of Rispens and the pathogenic MDV isolates in single and mixed infections. In the second experiment, a Rispens virus specific qPCR test was used to measure the vaccine take in invasive and non-invasive samples and the long-term viral kinetics of the Rispens virus in the field. Co-infection levels of Rispens and pathogenic GaHV-2 in the field and the possibility of establishment of Rispens virus in unvaccinated broiler flocks were also examined. Experiment one used 236 commercial ISA Brown chickens having maternal antibody directed against Rispens vaccine in 12 isolators. Chicks were vaccinated or not vaccinated with Rispens vaccine at hatch and challenged with vMDV isolate MPF57, vvMDV isolate FT158 at 5 days of age or left unchallenged. Each of the six treatment combinations was replicated in two positive pressure isolators.
Publication Type: Thesis Doctoral
Field of Research Codes: 070704 Veterinary Epidemiology
070205 Animal Protection (Pests and Pathogens)
070712 Veterinary Virology
Rights Statement: Copyright 2015 - Sithara Ralapanawe
HERDC Category Description: T2 Thesis - Doctorate by Research
Statistics to Oct 2018: Visitors: 70
Views: 734
Downloads: 32
Appears in Collections:School of Environmental and Rural Science
Thesis Doctoral

Files in This Item:
11 files
File Description SizeFormat 
open/MARCXML.xmlMARCXML.xml3.84 kBUnknownView/Open
open/SOURCE03.pdfAbstract467.27 kBAdobe PDF
Download Adobe
open/SOURCE04.pdfThesis1.93 MBAdobe PDF
Download Adobe
1 2 Next
Show full item record

Page view(s)

checked on Dec 29, 2018


checked on Dec 29, 2018
Google Media

Google ScholarTM






Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.